Ancobon

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Metastatic Colorectal CancerGlioblastomaGliomaCryptococcal Meningitis

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

1

Vectibix

Amgen

Phase 3

452

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

943

Erbitux

IImclone

Phase 3

1134

Sutent

Pfizer

Phase 3

35

Lumakras

Amgen

Phase 3

26

Trifluridine/tipiracil

AbbVie

Phase 3

137

Zocor

OOrganon and Co

Phase 3

48

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

29

Alinia

RRomark Laboratories L.C.

Phase 3

110

AK112

SSummit Therapeutics

Phase 3

3Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cryptococcal Meningitis11 trials

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000708·120 enrolled

Dexamethasone in Cryptococcal Meningitis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000776·36 enrolled

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

Completed·Pfizer·N/A·NCT00002113·64 enrolled

Show 8 more trials

AmB Dose for Cryptococcal Meningitis

Unknown status·SShanghai Public Health Clinical Center·Phase 3·NCT04140461·40 enrolled

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000639·400 enrolled

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Completed·Pfizer·N/A·NCT00002075

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

Completed·Pfizer·N/A·NCT00002305

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

Unknown status·AANRS, Emerging Infectious Diseases·Phase 2/3·NCT01715922·41 enrolled

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Unknown status·PPeking Union Medical College Hospital·N/A·NCT05471063·30 enrolled

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Completed·IInterMune·Phase 2·NCT00012467·60 enrolled

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Completed·UUniversity of Minnesota·Phase 2·NCT06414512·48 enrolled

Glioma2 trials

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Completed·—·Phase 1·NCT01172964·15 enrolled

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Completed·—·Phase 1·NCT02015819·16 enrolled

Glioblastoma1 trial

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

Withdrawn·NNRG Oncology·Phase 2/3·NCT04105374

Liposomal Amphotericin B1 trial

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Not yet recruiting·—·Phase 3·NCT06525389·428 enrolled

Solid Tumors1 trial

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Suspended·AAnaeropharma Science, Inc.·Phase 1/2·NCT01562626·75 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News